References
Pal P, Bathia J, Giri PP, et al. Macrophage activation syndrome in pediatrics: 10 years data from an Indian Center. Int J Rheum Dis. 2020;23:1412–16.
Ramanan AV, Sawhney S, Murray KJ. Central nervous system complications in two cases of juvenile onset dermatomyositis. Rheumatology. 2001;40:1293–8.
Elizabeth FE, Kamphuis SS, Prakken BJ, et al. Case report: Severe central nervous system involvement in juvenile dermatomyositis. J Rheumatol. 2003;30:2059–63.
Di Muzio B, Rasuli B. Central Nervous System Vasculitis. Accessed on July 20, 2022. Available from: http://radiopaedia.org/article/33353
Deakin CT, Campanilho-Marques R, Simou S, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheumatol. 2018;70:785–93.
Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jagwani, H., Mondal, A. & Pal, P. Juvenile Dermatomyositis With Macrophage Activation and Severe Encephalopathy. Indian Pediatr 59, 725–726 (2022). https://doi.org/10.1007/s13312-022-2606-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-022-2606-2